Join us at the Alumni Reception 

Join us at our Alumni Reception on Sunday, September 29th, from 9-11 p.m., at the Yardbird Table & Bar.  All former and current residents, fellows, staff, spouses, companions and friends are welcome. 


Where to Find Our Booth

Find Cleveland Clinic's booth #13040 by the Grand Concourse Entrance near AACR to connect and learn more about our program. 

Date

Time

First Author

Title

Abstract / Poster Number

Location
May 30th 4:57 PM CDT Mina Lobbous, MD, MSPH INB-200: Phase 1 study of gene-modified autologous gamma-delta (γδ) t cells in newly diagnosed glioblastoma multiforme (GBM) patients receiving maintenance temozolomide (TMZ). 2007 S100bc
May 31st 1:15 PM CDT Shlomo Koyfman, MD Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT). 6000 S100a
June 1st 9:00 AM - 12:00 PM CDT James Isaacs, MD A phase Ib study to assess the safety and efficacy of autologous tumor infiltrating lymphocytes (lifileucel) with adjuvant pembrolizumab (PEMBRO) for treatment of immunotherapy naïve patients with high-risk clinical stage IIIb-d resectable melanoma (MEL). TPS9611 / 84b Hall A
June 1st 9:00 AM - 12:00 PM CDT Deepa Jagadeesh, MD Long-term follow-up of the phase 2 ELM-2 study: Odronextamab for patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL) 7049 / 232 Hall A
June 2nd 1:30 PM - 4:30 PM CDT Wen Wee Ma, MBBS Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2 study. 2575 / 222 Hall A

Date

Time

Title

Abstract / Poster Number

Location
May 30th 4:57 PM CDT INB-200: Phase 1 study of gene-modified autologous gamma-delta (γδ) t cells in newly diagnosed glioblastoma multiforme (GBM) patients receiving maintenance temozolomide (TMZ). 2007 S100bc
May 31st 1:15 PM CDT Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT). 6000 S100a
June 1st 9:00 AM - 12:00 PM CDT A phase Ib study to assess the safety and efficacy of autologous tumor infiltrating lymphocytes (lifileucel) with adjuvant pembrolizumab (PEMBRO) for treatment of immunotherapy naïve patients with high-risk clinical stage IIIb-d resectable melanoma (MEL). TPS9611 / 84b Hall A
June 1st 9:00 AM - 12:00 PM CDT Long-term follow-up of the phase 2 ELM-2 study: Odronextamab for patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL) 7049 / 232 Hall A
June 2nd 1:30 PM - 4:30 PM CDT Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2 study. 2575 / 222 Hall A

Sec-4 - D: Lorem ipsum dolor sit amet, consectetur adipiscing elit

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.

Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

 

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in.


Renowned for its expertise, the Cleveland Clinic Cancer Institute provides multidisciplinary cancer care, offers access to cutting-edge clinical trials, and support programs across Northeast Ohio, Florida, Abu Dhabi and coming soon in London, aiming to help cancer patients improve their quality of life and achieve long-term survival.

Cleveland Clinic provides world-class care to patients with cancer. Our nationally ranked cancer program is at the forefront of new and emerging clinical, translational and basic cancer research. 


Dedicated to Advancing Cancer Care and Research

As a multidisciplinary, collaborative practice, we are committed to working with you to provide the best care for your patients, and to educate the next generation of medical professionals at all our facilities worldwide.

25-CNR-6011358 ASCO 2025 Graphic-pre-email-2-REV.jpg

Abstracts to Watch for at ASCO 2025

The cancer treatment landscape is changing, with new approvals coming fast and furious. This year's ASCO conference is an opportune time to hear the latest advances in treatments for solid tumors as well as blood cancers.

Discover the latest advances in GI, head and neck, lung and thoracic cancers as well as melanoma and hematologic malignancies in our "must see" abstracts. 


Save the Date

All former and current residents, fellows, staff, friends and spouses / companions of Cleveland Clinic are welcome to attend our Alumni Reception on Sunday, September 29th, from 9-11 p.m., at the Yardbird Table & Bar. 


Top 10 Abstracts to Watch for at ASCO 2025
The cancer treatment landscape is changing, with new approvals coming fast and furious. This year's ASCO conference is an opportune time to hear the latest advances in treatments for solid tumors as well as blood cancers. Discover the latest advances in GI, head and neck, lung and thoracic cancers as well as melanoma and hematologic malignancies in our "must see" abstracts. As you plan your time at ASCO, keep an eye out for these top research studies highlighted by Cleveland Clinic leadership.
We're excited to be back at ASCO this year! Visit us at Booth #13040 to recharge, network and learn more about our program.
Date Time Title Abstract/Poster# Location
May 31st
9 AM - 12 PM
 Risk of Intracranial Hemorrhage with DOACs vs LMWH in patients with cancer-associated thrombosis and brain metastases 2034 Hall A
May 31st
9 AM - 12 PM
 A Phase II Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma: ECOG-ACRIN EA2187 4115 Hall A
May 31st
1:30-4:30 PM
 Comparable efficacy and safety of taletrectinib for advanced ROS1+ non–small cell lung cancer across pivotal studies and between races and world regions. 8643 Hall A
May 31st
1:15 PM
 Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT) 6000 S100a
June 3rd
12:09 PM
 Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201 7508 S100bc


Roy Miller, MD

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis.

Roy Miller, MD

Our team is involved in many posters and presentations. 

View our schedule

Renowned for its expertise, the Cleveland Clinic Cancer Institute provides multidisciplinary cancer care, offers access to cutting-edge clinical trials, and support programs across Northeast Ohio, Florida, London, and Abu Dhabi aiming to help cancer patients improve their quality of life and achieve long-term survival.

Lorem ipsum dolor sit amet, consectetur adipiscing elit

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.

22-CNR-2819722-CQD-Hero-650x450-1.jpg

Hairy Cell Leukemia Complicated by Severe COVID-19: A Case Study

Novel three-drug regimen used to manage life-threatening developments

Consult QD

A site for physicians and healthcare professionals. Discover the latest cancer research insights, innovations and emerging advances from Cleveland Clinic Cancer Center specialists.

Read our most recent cancer articles on Consult QD

Roy Miler, MD

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore e.

S12: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et

Dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur. Tityre, tu patulae recubans sub tegmine fagi dolor. Quae vero auctorem tractata ab fiducia dicuntur. Salutantibus vitae elit libero, a pharetra augue. Quam diu etiam furor iste tuus nos eludet? Quisque placerat facilisis egestas cillum dolore. Contra legem facit qui id facit quod lex prohibet. Praeterea iter est quasdam res quas ex communi. Fabio vel iudice vincam, sunt in culpa qui officia. Ambitioni dedisse scripsisse iudicaretur.

Inmensae subtilitatis, obscuris et malesuada fames. Paullum deliquit, ponderibus modulisque suis ratio utitur. Nihil hic munitissimus habendi senatus locus, nihil horum? Qui ipsorum lingua Celtae, nostra Galli appellantur. Pellentesque habitant morbi tristique senectus et netus. Etiam habebis sem dicantur magna mollis euismod.

Cum ceteris in veneratione tui montes, nascetur mus. Morbi fringilla convallis sapien, id pulvinar odio volutpat. Lorem ipsum dolor sit amet, consectetur adipisici elit, sed eiusmod tempor incidunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation. Quid securi etiam tamquam eu fugiat nulla pariatur.

Cum sociis natoque penatibus et magnis dis parturient. Cras mattis iudicium purus sit amet fermentum. Magna pars studiorum, prodita quaerimus. Curabitur est gravida et libero vitae dictum. Ullamco laboris nisi ut aliquid ex ea commodi consequat.

Roy Miler, MD

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore e.

S12: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et

Dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur. Tityre, tu patulae recubans sub tegmine fagi dolor. Quae vero auctorem tractata ab fiducia dicuntur. Salutantibus vitae elit libero, a pharetra augue. Quam diu etiam furor iste tuus nos eludet? Quisque placerat facilisis egestas cillum dolore. Contra legem facit qui id facit quod lex prohibet. Praeterea iter est quasdam res quas ex communi. Fabio vel iudice vincam, sunt in culpa qui officia. Ambitioni dedisse scripsisse iudicaretur.

Inmensae subtilitatis, obscuris et malesuada fames. Paullum deliquit, ponderibus modulisque suis ratio utitur. Nihil hic munitissimus habendi senatus locus, nihil horum? Qui ipsorum lingua Celtae, nostra Galli appellantur. Pellentesque habitant morbi tristique senectus et netus. Etiam habebis sem dicantur magna mollis euismod.

Cum ceteris in veneratione tui montes, nascetur mus. Morbi fringilla convallis sapien, id pulvinar odio volutpat. Lorem ipsum dolor sit amet, consectetur adipisici elit, sed eiusmod tempor incidunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation. Quid securi etiam tamquam eu fugiat nulla pariatur.

Cum sociis natoque penatibus et magnis dis parturient. Cras mattis iudicium purus sit amet fermentum. Magna pars studiorum, prodita quaerimus. Curabitur est gravida et libero vitae dictum. Ullamco laboris nisi ut aliquid ex ea commodi consequat.

Cancer-Advances-Podcast-Icon-d.jpg

Learn more

Consult QD

A site for physicians and healthcare professionals. Discover the latest cancer research insights, innovations and emerging advances from Cleveland Clinic Cancer Center specialists.

Read our most recent cancer articles on Consult QD

S14 - A: Nullam in enim ullamcorper, efficitur dui a, fermentum erat. Cras in massa eget nisi imperdiet hendrerit vel interdum tellus. Ut pellentesque neque ipsum, quis fringilla nisl volutpat vel. Cras et luctus ipsum, quis blandit ligula. Morbi elementum tincidunt nibh eu lobortis. Ut consectetur ut libero sed sagittis.

Subscribe

S14 - A: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et

Dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Join us at the Alumni Reception 

Join us at our Alumni Reception on Sunday, September 29th, from 9-11 p.m., at the Yardbird Table & Bar.  All former and current residents, fellows, staff, spouses, companions and friends are welcome. 

RSVP

Access Barriers to Transplant Affect Outcomes in AML

Access Barriers to Transplant Affect Outcomes in AML

Socioeconomic disparities have a notable influence on access to allogeneic hematopoietic cell transplant.
Efficacy and Safety Outcomes of Bispecific Antibodies

Efficacy and Safety Outcomes of Bispecific Antibodies

Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma. 
Real-World Study Examines Optimal Sequencing and Timing of Treatments for Relapsed/Refractory Multiple Myeloma
Bispecific Antibody Glofitamab Combination with Chemoimmunotherapy Safe and Effective for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy
Major Study Finds CAR T-Cell Therapy Safe and Effective for Older Patients With B-Cell Acute Lymphoblastic Leukemia

Major Study Finds CAR T-Cell Therapy Safe and Effective for Older Patients With B-Cell Acute Lymphoblastic Leukemia

Offers a new option for patients 60 and older with relapsed/refractory disease.
Careers

Join Our Cancer Team

Together we can deliver world-class care.
CA icon.jpg

Listen to our Podcast

Exploring recent oncology clinical advances.

Read Cancer Research Insights

Discover the latest breakthroughs and innovations. 

Cleveland Clinic Children’s Hospital for Rehabilitation

Address:
18101 Lorain Ave
Cleveland, OH 44111

Hours:
Open 24 hours

Phone:
(216) 476-7000

Emergency room:
Open 24 hours

Cleveland Clinic Children’s Hospital for Rehabilitation

Address:
18101 Lorain Ave
Cleveland, OH 44111

Hours:
Open 24 hours

Phone:
(216) 476-7000

Emergency room:
Open 24 hours

Cleveland Clinic Children’s Hospital for Rehabilitation

Address:
18101 Lorain Ave
Cleveland, OH 44111

Hours:
Open 24 hours

Phone:
(216) 476-7000

Emergency room:
Open 24 hours

Location Map

Cleveland Clinic at ASCO 2025

Connect with us at booth #13040

Cancer Advances

Cancer Advances is our printed publication that showcases Cleveland Clinic Cancer Center's high-impact, translational cancer research and innovative therapies, from cancer vaccine development to advances in cancer genomics, rare disease treatment, and more.

Read our Winter 2022 Edition

Subscribe to the Cancer Advances eNewsletter to get the latest Cleveland Clinic cancer-related research and insights.